Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Low-density lipoprotein particle number and risk for cardiovascular disease.Curr Atheroscler Rep. 2004; 6: 381-387
- Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women.Circulation. 2002; 106: 1930-1937
- Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the Cardiovascular Health Study.Arterioscler Thromb Vasc Biol. 2002; 22: 1175-1180
- Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial.Atherosclerosis. 2002; 160: 41-48
- Effect of pravastatin on LDL particle concentration as determined by NMR spectroscopy: a substudy of a randomized placebo controlled trial.Eur Heart J. 2003; 24: 1843-1847
- Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects.Arch Intern Med. 1999; 159: 1893-1900
- Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density.Circulation. 1999; 99: 1959-1964
- Bile sequestrant therapy alters the compositions of low-density and high-density lipoproteins.Metabolism. 1979; 28: 221-229
- Colestipol-induced changes in LDL composition and metabolism. II. Studies in humans.J Lipid Res. 1989; 30: 225-238
- Hypercholesterolemia with cholesterol-enriched LDL and normal levels of LDL-apolipoprotein B. Effects of the step I diet and bile acid sequestrants on the cholesterol content of LDL.Arterioscler Thromb Vasc Biol. 1996; 16: 517-522
The lipid research clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351–64.
- Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.N Engl J Med. 1990; 323: 1289-1298